{
  "retracted": false,
  "timestamp": 1543622400000,
  "updates": [
    {
      "timestamp": 1586869182484,
      "identifier": {
        "doi": "10.1158/2159-8290.cd-18-1291"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1158/2159-8290.cd-17-0699"
  },
  "publisher": "American Association for Cancer Research (AACR)",
  "title": "Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms"
}
